Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide

SLS-002 demonstrated early and persistent clinically meaningful reductions in symptoms of depression and acute suicidality Robust Response and Remission Rates were observed using the...

Related Keywords

New York ,United States ,Davidv Sheehan ,Tim Whitaker ,Anthony Marciano ,Lifesci Advisors ,Seelos Therapeutics Inc ,Javelin Pharmaceuticals Inc Hospira ,Agency For Healthcare Research ,Exchange Commission ,Nasdaq ,Prnewswire Seelos Therapeutics Inc ,Remission Rates ,Depression Rating Scale ,Acute Suicidal Ideation ,Major Depressive Disorder ,Chief Medical Officer ,Key Efficacy ,Administered Dissociative States Scale ,Sedation Scale ,Post Traumatic Stress ,Javelin Pharmaceuticals ,Healthcare Research ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Sci Advisors ,Markets ,